Patent ID: 8742101

Claim:
A method of treating a host infected with HCV, comprising administering an effective amount of a ribofuranonucleoside of Formula (III): or a pharmacologically acceptable salt thereof, wherein: R, R 2 *, and R 3 * are each independently H, mono-, di-, or triphosphate; phosphonate; or optionally substituted alkyl, lower alkyl, optionally substituted alkenyl or alkynyl, acyl, —C(O)-(alkyl), —C(O)(lower alkyl), —C(O)-(alkenyl), or —C(O)-(alkynyl); X is O; R 2′ is H; optionally substituted alkyl, alkenyl, or alkynyl; and Base is selected from the group consisting of: wherein: each R′ and R″ independently is H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halogen, halogenated alkyl, OH, CN, N 3 , carboxy, C 1-4 alkoxycarbonyl, NH 2 , C 1-4 alkylamino, di(C 1-4 alkyl)amino, C 1-6 alkoxy, C 1-6 alkylsulfonyl, or (C 1-4 alkyl) 0-2 aminomethyl; each W is Cl, Br, I, F, halogenated alkyl, alkoxy, OH, SH, O-alkyl, S-alkyl, O-alkenyl, O-alkynyl, S-alkenyl, S-alkynyl, —OC(O)NR 4 R 4 , O-acyl, S-acyl, CN, SCN, OCN, NO 2 , N 3 , NH 2 , NH(alkyl), N(alkyl) 2 , NH-cycloalkyl, NH-acyl, CONH 2 , CONH(alkyl), or CON(alkyl) 2 ; and each R 4 is independently H, acyl, or C 1-6 alkyl.